Immune markers that predict who will get severe acute pancreatitis
Immune Signatures and Clinical Outcomes in Acute Pancreatitis
Researchers will measure immune system proteins in people admitted with acute pancreatitis to spot early signs of who may become severely ill.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-11333744 on NIH RePORTER |
What this research studies
You would be followed after hospital admission for acute pancreatitis while researchers collect blood samples and clinical information at multiple hospitals. Lab tests will measure a panel of immune proteins (including angiopoietin-2, hepatocyte growth factor, interleukin-8, resistin, and TNF receptor-1) and researchers will use bioinformatics to find patterns linked to severe disease. The study is a prospective multi-center observational cohort designed to validate an early blood-marker panel and to explore immune pathways driving organ failure. Results could help doctors identify high-risk patients earlier and point to new treatment targets.
Who could benefit from this research
Good fit: Ideal candidates are adults recently admitted to the hospital with acute pancreatitis who can provide blood samples and clinical follow-up information.
Not a fit: People without acute pancreatitis or those fully recovered before enrollment would not directly benefit from this study.
Why it matters
Potential benefit: If successful, this work could help doctors identify patients at high risk for severe pancreatitis earlier so they can receive closer monitoring or be offered targeted trials.
How similar studies have performed: Pilot work by the team found a multi-cytokine blood panel that predicted severe pancreatitis with high accuracy, but it needs multi-center validation.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Papachristou, Georgios I — Ohio State University
- Study coordinator: Papachristou, Georgios I
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.